Last update: May 22, 2019
Minimal risk for breastfeeding and infant.
It is a metabolite of Bromhexine (Schaefer 2007 p72).
Effectiveness of this drug has not been established (Prescrire 2017, DGF 2011, INSALUD 2001).
Oral administration two to three times a day.
At latest update, relevant published data on excretion into breast milk were not found.
Its high percentage of protein binding and high volume of distribution make it very unlikely that significant amounts will be transferred to milk.
The manufacturer confirms that it is unlikely that it could affect the breastfeed infant.
Known adverse reactions are rare and mild. Authorized for use in children.
Secretion of Prolactin and other hormones have not been affected by taking this medication (Tuimala 1981).
Expert authors consider it safe during breastfeeding (Schaefer 2007 p644).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM